We are IntechOpen,
the world's leading publisher of
Open Access books
Built by scientists, for scientists

4,800
Open access books available

122,000
International authors and editors

135M
Downloads

Our authors are among the

154
Countries delivered to

TOP 1%
most cited scientists

12.2%
Contributors from top 500 universities

CLARIVATE ANALYTICS

BOOK CITATION INDEX

INDEXED

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Innate Lymphocyte Effectors (Natural Killer, Natural Killer T and γδ T Cells) in Infection and Myocarditis

S.A. Huber
Department of Pathology, University of Vermont
Colchester, Vermont
U.S.A.

1. Introduction

Myocarditis is defined as an inflammation of myocardium where the infiltrating leukocytes are intimately associated with cardiomyocyte necrosis or drop-out (Liu, 2005; Woodruff, 1980). Cardiac damage may be minimal and self-limiting or may result in chronic fibrosis and cardiac dysfunction leading to death in children and young adults (Eckart et al., 2004; Fabre, 2006; Solberg et al., 2010). As discussed in other chapters of this book, infections with a highly diverse group of viruses, bacteria, fungi, and worms have been implicated in infectious myocarditis (Friman et al., 1995). Enteroviruses and adenoviruses are usually considered as the predominant viral etiological agents, and are associated with approximately 80% of clinical myocarditis where a viral infection is documented. However, virtually any virus infection may initiate myocarditis (Bowles et al., 2003; Woodruff, 1980). While seasonal influenza virus is only a minor etiological agent in myocarditis, evidence from the most recent influenza H1N1 pandemic (Vila de Muga et al., 2010; Wiegand et al., 2010; Zheng et al., 2010) suggests a higher incidence of both mortality and morbidity, and accounts for 5% of complications in infected children (Zheng et al., 2010).

Myocardial injury results either directly from replication and induction of death or dysfunction in infected cardiocytes, or from host responses to infection (Huber, 2010). Although anti-viral host responses (innate or adaptive) are intended to control and eliminate the infection, cytokines and by-products such as nitric oxide or oxygen free radicals may also damage adjacent uninfected cells (Szalay et al., 2006). Innate immunity is the initial host response to infection and usually occurs within hours or days of virus introduction. The major characteristic of the innate response, besides its rapidity, is that it is broadly reactive to multiple infectious agents. While it is highly unlikely that innate immunity can completely eliminate the infection, it can suppress microbial replication until the far more potent and highly specific adaptive immune response kicks in. The reason for this is quite simple, viruses replicate rapidly with, for example, one picornavirus infected cell in tissue culture producing up to a million progeny virions within 18-24 hrs. In vivo, such rapid and uncontrolled growth could result in extensive tissue injury or death of the organism prior to a useful adaptive immune response being established since during a primary immune response, production of meaningful numbers of virus-specific T cells could

take 7-10 days after virus inoculation. The best known innate immunity results from microbial products binding to and activating Toll-Like Receptors (TLR) or RNA helicases (RIG-I and MDA-5) which activate transcription factors (NFkB) leading to expression of cytokines (TNFα, IL-1β and IL-6) and nitric oxide (Hosoi et al., 2004; Michelsen et al., 2004); or interferon response factors (IRF3/7) leading to expression of type 1 interferons (IFNα/β) RANTES and IP-10 (O'Neill, 2004; Vogel et al., 2003). These roles for TLR are discussed elsewhere. This review will concentrate on lymphocytes belonging to the innate immune response and discuss their role in myocarditis. These lymphocytes include natural killer (NK), natural killer T (NKT) and γδ T cells.

2. Natural killer cells

Natural killer (NK) cells are capable of distinguishing between infected/transformed cells and uninfected/non-transformed cells and are able to kill the former using perforin or granzyme dependent mechanism (Topham & Hewitt, 2009). The best recognized mechanism for NK cell activation is through Type 1 interferons (IFNα/β). Type 1 interferons upregulate multiple interferon response factors (IRFs) and two of these IRFs are strongly implicated in NK cell proliferation and activation (Taniguchi et al., 2001). NK cell numbers are dramatically reduced in IRF2-/- mice (Lohoff et al., 2000). NK cell numbers are also reduced in IRF1-/- mice but in this case, the defect is not inherent in the NK cell progenitor since adoptive transfer of IRF1-/- bone marrow into wild-type mice results in NK cell proliferation (Ogasawara et al., 1998). Rather, IRF-1 appears to control IL-15 expression in bone marrow stromal cells and IL-15 promotes NK cell generation. Similarly, other cytokines including IL-2, IL-12 and IL-18 promote NK cell responses (Agaugue et al., 2008). In contrast to IRF1, IRF2 is inherently important in the NK cell progenitor since adoptive transfer of IRF2-/- bone marrow into wild-type recipients fails to generate NK cells. How NK cells recognize aberrant cells has received substantial study since these effectors are non-T cells, lack the T cell receptor and CD3, and do not undergo genetic recombination of recognition receptors (Biron et al., 1999; Orange et al., 2002). NK cells express substantial numbers of both activating and inhibiting receptors (reviewed in (Lanier, 2008)), and despite lacking classical T cell receptors, NK cells can recognize microbial molecules. Examples include NKp46 recognition of the influenza hemagglutinin protein (Mandelboim et al., 2001), Ly49H recognition of m157 (mCMV) (Arase et al., 2002), NKp44/NKp46 recognition of NDV hemagglutinin-neuraminidase (Jarahian et al., 2009), and Ly49P recognition of m04 (mCMV) (Kielczewska et al., 2009). NK activation receptors pair with ITAM-bearing DAP12, FcεRI-γ and CD3-ζ signaling molecules. Stimulation of the NK activating receptors leads to phosphorylation of the ITAM components and recruitment of Syk and ZAP-70. This results in actin cytoskeletal reorganization, which promotes secretion of preformed cytokines. The cytokines primarily produced by NK cells are IFNγ/TNFα, or perforin/granzyme. Activation also increases transcription of cytokine genes. In contrast, inhibitory NK receptors are either monomeric type 1 glycoproteins of the immunoglobulin superfamily [examples include: killer cell immunoglobulin-like receptors (KIRs) and leukocyte immunoglobulin-like receptors (LILRs)] or type II glycoproteins containing a C-type lectin—like scaffold [examples include: Ly49 and CD94-NKG2A]. Both types of receptor contain immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in their intracellular domains which, when activated, recruit tyrosine phosphatases that block the phosphorylation steps initiated by the NK activating receptors and thus inhibit NK cell functions (Lanier, 2008).

NK inhibitory receptors recognize major histocompatibility complex class I (MHC I) molecules which represents one mechanism by which NK cells distinguish between infected and normal cells, as many viruses attempt to evade the immune system through down-regulation of MHC molecules (Hewitt, 2003).

Evidence for a major role of NK cells in clinical myocarditis is rather weak. NK cells were not observed in heart tissue from 18 cases of biopsy proven myocarditis (Chow et al., 1989). Other studies have found either increased numbers of NK like cells in peripheral blood of dilated cardiomyopathy patients (Yokoyama, 1988) or diminution of NK cell activity in such patients (Maisch et al., 1985). Studies in patients with Chagas' disease find no alteration in NK cells early in the disease but an increase in these innate effectors occurs at later stages (Sathler-Avelar et al., 2003). One potential problem with clinical studies is that diagnosis of myocarditis or dilated cardiomyopathy is a relatively late event in the disease process and may be quite removed from the initiating acute infection (Woodruff, 1980). In fact, while viral genomic sequences can be detected in clinical heart biopsies for months and possibly for years, it is rare for infectious virus to be isolated from the hearts of myocarditis patients. Any role for NK cells may be over by the time human tissue is studied. The best evidence that NK cells might participate in viral myocarditis comes from mouse models. These studies indicate that NK cells are important in controlling coxsackievirus B infections in vivo (Gauntt et al., 1988; Gauntt et al., 1989; Vella & Festenstein, 1992) as depletion of these cells substantially increases virus titers in the heart or pancreas. The ability of NK cells to suppress virus infection may relate to their cytolytic activity to infected cardiocytes. Rapid elimination of infected cells before virus replication is complete would restrict the number of progeny virions produced and therefore limit the next cycle of infection. The second mechanism by which NK cells may help control virus infection is through either augmenting or accelerating the adaptive immune response to the virus. NK cells directly interact with both dendritic cells and activated T cells causing maturation of the dendritic cells and increased activation of the T cells (Zingoni et al., 2005). Interactions occur through up-regulation of OX40L on the NK cells and OX40 on activate CD4+ lymphocytes. Also, NK cells contain high concentration of pre-formed cytokines which can be rapidly released upon NK receptor engagement and these cytokines provide the environment necessary for optimal adaptive immunity development. As with the mouse model of CVB3 myocarditis, NK cells also control spread of Trypanosoma cruzi in the mouse model of Chagas' disease (Brener & Gazzinelli, 1997).

3. Natural killer T and γδ T cells

The other two major innate lymphocyte populations are natural killer T (NKT) and γδ T cells. NKT cells primarily recognize lipid antigens presented by CD1d molecules. The γδ T cells represent a more diverse population and in many cases, the antigen specificity of these cells is not known. However, as discussed below, the γδ T cells known to be involved in experimental viral myocarditis are also CD1d restricted. For this reason, description of the CD1 family of molecules is provided followed by discussion of the NKT and γδ T cells in innate immunity.

3.1 CD1 molecules and regulation of their expression

There are five distinct CD1 molecules, CD1a, CD1b, CD1c, CD1d and CD1e (Figure 1). Although these different molecules most likely arose from a single common ancestral gene

and are located as a cluster of genes on the same chromosome (De Libero & Mori, 2003), they share only approximately 30% homology and have distinct expression patterns and functional characteristics (Blumberg et al., 1995; Calabi et al., 1989; Kasmar et al., 2009). These proteins belong to a family of non-polymorphic, class I-like major histocompatibility complex (MHC) molecules (Boes et al., 2009). Humans express CD1a, CD1b, CD1c, CD1e (Group 1 CD1 molecules) and CD1d (Group 2 CD1 molecule). Mice express two isoforms of CD1d but lack any of the Group 1 CD1 molecules (Bradbury et al., 1990; Sugita et al., 1999). Other mammals express varying combinations of the different CD1 isoforms. For example, ruminants, such as cattle, express CD1a, three isoforms of CD1b and CD1e but lack either homologues of CD1c or CD1d (Van Rhijn et al., 2006). To date, all mammals have at least one CD1 molecule and a similar CD1-like molecule has been recently found in birds (Dvir et al., 2010). The wide distribution of CD1 expression among species underlines the importance of these molecules in immunity. A major difference between the non-classical CD1 molecules and the classical MHC I and MHC II molecules is that the latter molecules primarily present peptide antigens while CD1 molecules present amphipathic glycolipid (Kasmar et al., 2009; Kulkarni, 2010) and possibly hydrophobic peptide (Van Rhijn et al., 2009) antigens to T cells which provides a more comprehensive sampling of microbial products than the classical MHC molecules alone could provide. There are few CD1 genes (maximum of 12 but not all are present in all species) compared to the classical MHC molecules (>200), and CD1 proteins are highly conserved with few if any allelic variations. However, crystal structure analysis suggests that CD1 proteins have substantial flexibility and can conformationally change to present diverse microbial and self glycolipids (Zajonc et al., 2008).


Fig. 1. CD1 family of non-classical MHC class I-like molecules.

There are five known members of the CD1 family divided into Group 1 and Group 2 molecules. All CD1 molecules present lipid antigens, unlike classical MHC molecules which primarily present peptide antigens. All CD1 genes derive from a common ancestral gene.
Unlike the other four members of the CD1 family, CD1e is only found as a soluble form in endosomes where it aids in trimming phosphatidylinositol for presentation by CD1b (de la Salle et al., 2005). CD1a, b, and c molecules are expressed on myeloid cells while CD1d is

expressed on these cells and additionally on non-hemopoietic cells including cardiac myocytes and endothelial cells (Blumberg et al., 1995; Exley et al., 2001; Huber et al., 2003) . CD1 molecules structurally resemble class I MHC molecules since they consist of a single polypeptide chain coded by the CD1 gene and are associated with β2 microglobulin. However, antigen presentation more closely resembles class II MHC molecules since antigen loading occurs in the endosome pathway and is TAP independent (Boes et al. , 2009; Brutkiewicz et al., 1995; Odyniec et al., 2004). The CD1 extracellular domain has a deep antigen binding groove containing two to four hydrophobic pockets into which the alkyl lipid tails of antigens are inserted leaving the glycosylated portion available for T cell recognition (Cheng et al., 2006; Zajonc et al., 2003; Zajonc et al., 2008). The cytoplasmic tails of CD1b, CD1c and CD1d contain a tyrosine motif which directs these molecules to the late endosome while the CD1a cytoplasmic tail lacks this motif and directs this molecule to the early endosome. The difference in trafficking of the CD1 molecules may reflect an evolutionary process since bacteria localize to different cellular organelles and expression of CD1 isoforms to distinct endosome compartments should promote maximal capture and presentation of microbial antigens to host immunity (De Libero & Mori, 2003). CD1b presents bacterial lipids including mycobacterial mycolic acids (Beckman et al., 1994), lipoarabinomannan (Sieling et al., 1995), glucose monomycolate (Moody, 2001), and self-glycosphingolipids such as GM1 ganglioside (Shamshiev et al., 2000). CD1a and CD1c present bacterial phospholipids (Beckman et al., 1996). CD1d presents a bacterial sphingolipid from *Sphingomonas* (Kinjo et al., 2005), alphaproteobacterium from *N. aromaticivorans* (Mattner et al., 2008), glycolipids from *B. burgdorferi* (Kinjo et al., 2006), and a self-sphingolipid isogloboside (Mattner et al., 2005). The sphingolipid α-galactosylceramide (αGalCer) isolated from marine sponges, is the classical CD1d ligand (Kawano et al., 1997), but CD1d has also been shown to present an α-galactosyl-diacylglycerol of *B. burgdorferi* (BbGL-II) (Kinjo et al., 2008; Kinjo et al., 2006). Evidence for CD1 presentation of viral antigens is sparse despite the fact that CD1-restricted T cells have been shown to respond in various viral infections including HIV, HSV, influenza and picornavirus (De Santo et al., 2008; Exley et al., 2001; Li & Xu, 2008; Yuan et al., 2006). Indeed, it would be highly unlikely that CD1 could directly present picornavirus molecules since these are non-enveloped viruses and should therefore lack any potential for glycolipid or lipopeptide antigens. Possible explanations for CD1-restricted immune responses to viruses exist. For example, infection may promote cellular lipidation of virus proteins (Van Rhijn et al., 2005) or infection may cause increased expression of endogenous glycolipid antigens (De Libero et al., 2005; Paget et al., 2007). Lysosomal α-galactosidase A is an enzyme which degrades endogenous lipid antigens (Darmoise et al., 2010). However, subsequent to many infections, α-galactosidase A activity can be severely curtailed leading to endogenous lipid accumulation. This means that CD1d dependent innate immunity may be directed to both exogenous and endogenous antigens during infections.

Endogenous glycosphingolipids binding to CD1 include GM1 ganglioside, sulfatide, galactosylceramide, and sphingomyelin (Darmoise et al., 2010; De Libero & Mori, 2003; Franchini et al., 2007; Hegde et al., 2010; Roy et al., 2008). The self-glycosphingolipids are not only important as self-antigens for T cell activation, but their presence may stabilize and promote CD1 expression on the cell surface (De Libero & Mori, 2003). Unlike microbial glycolipids which require processing in the endosomes, glycosphingolipids can directly bind to CD1 molecules expressed on the cell surface and can displace glycolipids already in these surface CD1 molecules (De Libero & Mori, 2003). Although endogenous

glycosphingolipids have been primarily viewed as the probable self antigen in CD1-dependent immunity, recent studies by Pei et al (Pei et al., 2010) demonstrated that cell lines incapable of glycosphingolipid biosynthesis were nonetheless capable of activating CD1-restricted cells. Thus, the types of self antigen capable of activating the CD1-dependent innate immune response are likely to be broader than originally thought.

Group 1 CD1 molecules are not expressed on monocytes in the blood and recent studies have shown that serum immunoglobulin and lipids suppress expression of these molecules (Leslie et al., 2008; Smed-Sorensen et al., 2008). However, once monocytes leave the circulation, Group 1 CD1 molecules can be induced by signaling through TLR2 (Roura-Mir et al., 2005), TLR2/TLR5 agonists, or cytokines (GM-CSF and IL-4) (Moody, 2006). CD1d is not up-regulated by GM-CSF and IL-4 (Exley et al., 2001; Sallusto & Lanzavecchia, 1994). CD1d is constitutively expressed in dendritic cells, monocytes and macrophage, but levels can be further increased subsequent to infection (Dougan et al. , 2007; Durante-Mangoni et al., 2004; Huber et al., 2003; Skold & Behar, 2003). Such up-regulation depends upon signaling through TLR and cytokines (IFNγ, IFNβ, TNFα) (Raghuraman et al., 2006; Skold et al., 2005). While microbial infections can up-regulate CD1 expression, they can also result in CD1 down-regulation (Donovan et al., 2007; Raftery et al., 2006). Viruses are well-known for their ability to evade immunity through multiple different mechanisms (Alcami & Koszinowski, 2000; Antoniou & Powis, 2008; Vossen et al., 2002). While most investigations of immune evasion by viruses center on the adaptive immune response, viruses also interfere with innate immunity. The HIV Nef protein binds to CD1d decreasing CD1d transport to the cell surface (Hage et al., 2005). Similarly, HSV, suppresses CD1 expression by interrupting the CD1 recycling pathway (Yuan et al., 2006). Karposi sarcoma-associated herpesvirus (KSHV) uses its modulator of immune recognition (MIR) proteins to ubiquitinize the cytoplastic tail of the CD1d molecule leading to its endocytosis (Sanchez et al., 2005). Activation of TLR7/8 blocks CD1 expression at the protein and mRNA levels (Assier et al., 2007). Finally, infection can change the endosomal processing of glycolipids which could restrict antigen availability to CD1 molecules.

Unlike Group 1 CD1 molecules, CD1d can be expressed on non-hemopoeitic cells (Huber et al., 2003; Monzon-Casanova et al. ; Sikder et al., 2009) CVB3 infection augments CD1d expression on macrophage, dendritic cells and T cells (Huber, 2006). The virus also causes de novo CD1d expression on non-hemopoietic cells (cardiac endothelial cells and myocytes), but only in non-hemopoietic cells actively replicating virus. Uninfected myocytes/endothelial cells immediately adjacent to infected cells remain CD1d negative (Huber et al., 2003). The requirement for active virus replication strongly suggests that TLR signal pathways such as TLR3 (recognizing single stranded RNA) or TLR7/8 (recognizing double stranded RNA) are necessary. However, virus replication alone is insufficient. Mice or cells infected with a non-pathogenic variant of CVB3, H310A1 (Knowlton et al., 1996), fail to up-regulate CD1d either on hemopoeitic or non-hemopoeitic cells (Huber et al., 2003; Huber & Sartini, 2005b). A major difference between the non-pathogenic and pathogenic (H3) variants of CVB3 is that the pathogenic virus is a potent inducer of TNFα. Further studies showed that TNFα and H310A1 infection up-regulated CD1d expression whereas either TNFα or H310A1 infection alone did not. In the mouse model of CVB3 induced myocarditis, CD1d is required for cardiac inflammation and injury. Mice lacking CD1d fail to develop myocarditis despite high levels of virus replication in the heart (Huber et al., 2003). Since CD1d is up-regulated on both hemopoeitic and non-hemopoeitic cells subsequent to CVB3 infection, a major question is where expression of this molecule is most

important in pathogenesis. CD1d-restricted effectors are cytolytic to CVB3 infected cardiocytes in vitro and expression of CD1d on infected cardiocytes in vivo may contribute directly to their death through cytolytic T lymphocyte activity. To address this question, bone marrow transplantation was performed between wild-type (CD1d+/+) and CD1d-/- mice where either the hemopoeitic cells were CD1d+ and the non-hemopoeitic cells (heart) was CD1d- or the opposite (Huber, 2006). These studies showed that CD1d expression on both hemopoeitic and non-hemopoeitic cells contributed to heart disease, although CD1d expression on hemopoeitic cells was of primary importance. There are no published studies showing the importance of CD1in clinical myocarditis. It is therefore not possible to evaluate the significance of CD1-dependent innate immunity in the human disease. However, based on the tight control of CD1 for pathogenesis in the experimental disease, the strong association between various microbial infections and clinical myocarditis, and the importance of CD1-restricted immunity in many different microbial infections; future investigation into a role for CD1 in this disease would be warranted.

3.2 Natural killer T cells and CD1-restricted γδ T cells

Many T cells respond to CD1 molecules (Barral & Brenner, 2007; Kaufmann, 1996) and express either T cell receptors (TCR) consisting of α/β or γ/δ polypeptide chains. Group 1 CD1-restricted αβ T cells are clonally diverse with fine antigen specificity, recognition of both self and foreign lipid antigens and either double negative (CD4-CD8-) or single positive (CD4+ or CD8+) (Barral & Brenner, 2007; Kaufmann, 1996; Vincent et al., 2005). The αβ T cell response is slow, similar to classical MHC αβ T cell responses indicating that these CD1-restricted effectors probably do not belong to the innate immune system. There are two major populations of γδ T cells in humans (Vδ1 and Vδ2) with Vδ2 cells primarily present in the circulation and Vδ1 cells primarily found in tissues and intestine (Das et al., 2004). Subsets of both γδ populations recognize antigens in context of non-classical MHC class I-like molecules including group 1 CD1(Rincon-Orozco et al., 2005; Russano et al., 2007). Activation of the group 1 CD1 restricted effectors requires IL-12, NKG2D activation on the effector and adhesion molecule interactions (LFA3/CD2, LFA1/ICAM1) in addition to TCR engagement. Since mice lack Group 1 CD1 molecules, this species does not have Group 1 CD1-restricted immunity. However, these effectors may function in humans.

T cells reacting to CD1d (Group 2 CD1) are also diverse. CD1d-restricted natural killer T (NKT) cells are designated as either invariant NKT (iNKT, also known as Type 1) or diverse NKT (also known as Type 2) cells (Barral & Brenner, 2007; Kronenberg, 2005; Ronchi & Falcone, 2008; Taniguchi et al., 2010). Type 1 iNKT cells have a TCR comprised of a single type of TCRα chain (Vα14Jα18 for mice and Vα24Jα18 for humans) and one of a limited number of distinct TCRβ chains resulting in limited clonal diversity. In contrast, Type 2 NKT cells use TCR comprised of diverse α and β chains. iNKT cells comprise between 2-40% of CD3+ cells in various tissues (Bendelac et al., 2007; Terabe & Berzofsky, 2008), have a constitutively activated phenotype, and rapidly secret large amounts of cytokines (IFN-γ, IL-4, IL-17, IL-5, and IL-13) upon activation due to the presence of pre-formed cytokine mRNA in the cells (Kronenberg, 2005; Michel, 2007; Olson et al., 2009; Stetson et al., 2003). Three mechanisms of iNKT cell activation have been described (Figure 2). Direct activation involves recognition of microbial antigens presented by CD1d on antigen presenting cells (TCR-mediated). In contrast, indirect activation either involves microbial stimulation of antigen presenting cells to release cytokines (IL-12 and Type 1 IFN) and presentation of

self/altered self lipid antigens on CD1d; or cytokines (IL-12 and IL-18) in the absence of CD1d antigen presentation (Brigl et al., 2003). Both inflammation and TLR activation can affect expression of enzymes involved in lipid metabolism (Khovidhunkit et al., 2004; Salio et al., 2007) and this may either increase total self lipid in endosomes or alter self lipids making them appear more foreign to the immune system. The mechanism of iNKT cell activation can impact the types of cytokines released with direct CD1d activation resulting in both Th1 (IFNγ) and Th2 (IL-4/IL-13) release while indirect activation causes predominantly Th1 (IFNγ) expression (Brigl et al., 2003). iNKT cells producing Th2 cytokines modulate NK cells to express TGFβ and TGFβ promotes T regulatory cell activation(Chen et al., 2009; Monteiro et al., 2010). Thus, depending upon the mode of iNKT cell activation, these effectors can be either pro- or anti-inflammatory. Type 2 NKT cells also can have a Th1 or Th2 phenotype with corresponding cytokine profiles, and therefore may have either potentiating or protective roles in infections and autoimmune diseases (Arrenberg et al., 2009). A number of reports indicate that Type 1 and Type 2 NKT cells are antagonistic to each other and form a regulatory network to control adaptive immunity. Most reports suggest an anti-inflammatory role for Type 2 NKT cells which can be protective in autoimmune diabetes in NOD mice (Duarte et al., 2004), experimental allergic encephalomyelitis (Jahng et al., 2004) and Con-A induced hepatitis (Halder et al., 2007). Furthermore, while type 1 NKT cells may increase tumor immunosurveillance, Type 2 NKT cells may suppress anti-tumor immunity (Ambrosino et al., 2007; Terabe & Berzofsky, 2008). Activation pathways for γδ T cells can also be diverse with both direct antigen presentation in MHC or MHC-like molecules or indirect with minimal or no antigen presentation (Kaufmann, 1996). Unlike NKT cells, γδ T cells may either react to CD1 itself in the absence of any antigen or to antigen without presentation by MHC/MHC-like molecule involvement. Although both human and mouse γδ T cells have been found to recognize antigens presented by Group 1 CD1 and other non-classical MHC antigens (Chien & Konigshofer, 2007; Cui et al., 2009; Spada et al., 2000; Van Kaer et al., 1991), only this laboratory has reported a subpopulations of γδ cells (Vγ4 TCR) recognizing CD1d (Huber et al., 2003).


Fig. 2. Mechanisms for NKT cell activation.

There are three major mechanisms for activating NKT cells. Direct activation involves phagocytosis of microbes and binding of microbial lipids into the CD1d groove in the late endosome with transport of the CD1d-lipid complex to the antigen presenting cell surface. NKT cells activated through this pathway produce a broader range of Th1 and Th2 cytokines. A second pathway involves microbial stimulation of TLR on the antigen presenting cell which can both affect self-lipid expression/availability and stimulate cytokine expression from the antigen presenting cells. NKT cells stimulated by the recognition of self-lipid/CD1d and the cytokine milieu secrete primarily Th1 cytokines. The third mechanism is either not or substantial less dependent upon CD1d recognition by the NKT cells but NKT cell activation is primarily induced through cytokines alone.

3.3 NKT and γδ T Cells in myocarditis

Several cases of clinical cardiomyopathy have been reported where substantial numbers of γδ cells are in the inflammatory infiltrate (Eck et al., 1997; Takeda et al., 2008; Takeda et al., 2005). However, there is little direct evidence for a pathogenic role for these innate effectors in humans. As indicated above for NK cells, the lack of direct evidence for innate effectors in clinical myocarditis may simply reflect the fact that innate immunity should function early after infection and may disappear from the heart by the time that clinical symptoms are evident. In contrast to myocarditis in humans, substantial evidence implicates innate lymphocyte effectors in mouse models of coxsackievirus B3 (CVB3) and Borrelia burgdorferi (Lyme disease) myocarditis (Figure 3). As described above, mice lacking CD1d fail to develop myocarditis subsequent to CVB3-H3 (highly myocarditic variant of CVB3 (Knowlton et al., 1996)) infection despite high levels of virus replication in the heart (Huber et al., 2003). Infecting iNKT deficient mice with CVB3-H3 had no effect indicating that iNKT cells do not contribute to pathogenesis with this CVB3 variant. Surprisingly, CD1d deficient mice had significantly reduced numbers of activated γδ T cells belonging to the Vγ4 subset, and further analysis demonstrated that these Vγ4 cells are CD1d restricted as they killed CVB3-H3 infected CD1d+ but not infected CD1d- cardiac myocytes and cytotoxicity of the CD1d+ myocytes was blocked by anti-CD1d antibodies but not by antibodies to the classical MHC I and MHC II antigens (Huber, 2000; Huber et al., 2003). More importantly, activation of Vγ4 cells correlated to induction of CD4+IFNγ+ (Th1) virus-specific cells, which indicates that γδ cells might impact myocarditis through their effects on the antigen-specific, adaptive immune response (Huber & Sartini, 2005a; Huber et al., 2002). Previous studies had shown that heart-specific, autoimmune CD8+ cytolytic T lymphocytes are the primary immunopathogenic effector in CVB3 induced myocarditis (Guthrie et al., 1984; Henke et al., 1995; Huber & Lodge, 1984; Huber et al., 1988; Huber et al., 2002). These autoimmune CD8 cells kill uninfected cardiocytes through recognition of cardiac myosin epitopes (Huber & Gauntt, 2000) and can adoptively transfer myocarditis into uninfected recipients (Huber et al., 1987). However, the autoimmune CD8 T cell response is absolutely dependent on CD4+IFNγ+ cells (Huber et al., 2002). This is not surprising as many studies have shown that CD4+ Th1 cells promote CD8 T cell activation (Krawczyk et al., 2007; Serre et al., 2006). Although Vγ4 cells are required for generation of CD4+IFNγ+ cells, once the CD4+IFNγ+ cells exist, Vγ4+ cells are no longer necessary for autoimmune CD8 cell induction or myocarditis (Huber et al., 2002). The CVB3 model is not the only one showing that γδ T cells are required for immunopathogenic CD4 and CD8 T cell responses. Trypanosoma cruzi, the etiological agent in Chagas' disease, causes myocarditis with cardiac injury at least partially mediated by T cells and IFNγ (dos Santos et al., 2001; Marin-Neto et al., 2007; Ribeiro-Dos-

Santos et al., 2001; Soares et al., 2001). As with the CVB3 model, γδ cells are required for the pathogenic CD4 and CD8 responses in T. cruzi infections (Nomizo et al., 2006). However, unlike the CVB3 myocarditis model, the relevant γδ cell in T. cruzi infection expresses the Vγ1 T cell receptor. Why Vγ4 cells are operational in CVB3 disease while Vγ1 cells function in T. cruzi infection, is not currently known, but might reflect the difference between a virus and protozoa as the etiological agent. Nonetheless, the principle is the same: innate effectors control the activation of pathogenic antigen-specific adaptive immunity which subsequently causes cardiac damage.

The next question is how γδ cells control induction of adaptive immunity. Regulatory T cells (Tregs) are important negative immune modulators, constitute up to 10% of peripheral CD4+ T cells in naive mice and humans, and express CD25 (IL-2 receptor α chain) (Sakaguchi, 2005; Sakaguchi et al., 2008; Torgerson, 2006). There are several types of T regulatory cells which can basically be divided into natural (nTreg) and inducible (iTreg) populations. nTreg cells are generated in the thymus, and presumably arise from T cells with high affinity TCR for self antigens. nTreg cells are functionally mature when leaving the thymus and do not require antigen exposure peripherally to generate immunosuppressive activity. In contrast to nTreg cells, iTreg can be converted from effector T cell populations in the periphery subsequent to antigen challenge. The transcription factor, FoxP3, is usually associated with Treg cell development and transduction of exogenous FoxP3 into CD4+CD25- cells converts these cells into CD4+CD25+ Treg cells (Sakaguchi et al., 2008). Induction of FoxP3 expression and therefore, Treg cell activation depends upon the presence of TGFβ (Mantel & Schmidt-Weber, 2010). While FoxP3 is necessary for conversion of CD4+ cells to Treg cells, IL-2 is required for Treg cell maintenance/survival. Animals lacking either CD25 (IL-2R) or IL-2 develop lymphoproliferative and autoimmune diseases (Malek & Bayer, 2004) associated with a decrease in Treg cells. Three mechanisms have been proposed for Treg cell function (Sakaguchi et al., 2008). The first mechanism hypothesizes that Treg cells out-compete effector T cells for MHC-antigen complexes on antigen presenting cells which effectively blocks effector T cell activation. In the second mechanism, Treg cells directly interact with dendritic cells through CTLA4 which down-regulates required accessory molecule expression needed for successful antigen stimulation of effector T cells. Finally, Treg cell secretion of TGFβ or IL-10 may inhibit T cell differentiation (Ozdemir et al. , 2009; Ray et al., 2010).

CVB3 infection up-regulates CD1d on infected cardiac myocytes and myeloid cells. CD1d activates NKT and Vγ4 T cells which can either recognize CD1d on myocytes leading to myocyte death or interact with dendritic cells (DC) through CD1d to alter antigen presentation function of the dendritic cells or to produce cytokines. NKT cells may also activate NK cells. NK and NKT cells promote activation of Treg cells by promoting myeloid derived suppressor cell differentiation, while Vγ4 T cells have the opposite effect and either directly kill Treg cells through CD1d expressed on the Treg cell population or induce dendritic cell maturation and enhanced antigen presentation to adaptive immune (CD4, CD8) effectors. Treg cells inhibit activation of CD4+IFNγ+ (Th1) cells which are required for generation of cytolytic, autoimmune CD8 effector cells. The CD8 effector cells are the primary immunopathogenic mediator to cardiac injury in CVB3 induced myocarditis.

Treg cells prevent autoimmunity in myocarditis (Frisancho-Kiss et al., 2006; Huber et al., 2006; Wang, 2010). Distinct populations of innate effector T cells can have dramatically different effects on Treg cell responses. iNKT cells can promote Treg cell activation (Nowak et al., 2006; Roelofs-Haarhuis et al., 2004; Roelofs-Haarhuis et al., 2003). Under appropriate

stimulation (see Figure 2), iNKT cells produce IL-13, a Th2 cytokine, which can induce TGFβ production from CD11b+Gr-1+ myeloid derived suppressor cells. TGFβ promotes FoxP3 expression and Treg cell differentiation (Mantel & Schmidt-Weber, 2010). Indirectly, NKT cells activate NK cells (Carnaud et al., 1999) and subpopulations of NK cells suppress adaptive immunity either through their effects on dendritic cells or T cells (Flodstrom-Tullberg et al., 2009; Lunemann et al., 2009). CD1d and NKT cells are crucial to Treg cell development (Sonoda et al., 1999), and treating mice with αGalCer increases Treg cell activation (La Cava et al. , 2006) and suppresses autoimmune diabetes in NOD mice (Cardell, 2006; Ly et al., 2006). NKT cells secret high levels of TGFβ and IL-10 (Sonoda et al., 2001; Stein-Streilein et al., 2000) which alter dendritic cell (DC) cytokine (IL-10) and accessory molecule (CD40, CD80 and/or CD86) expression (Kumanogoh et al., 2001; McGuirk & Mills, 2002; Salomon et al., 2000) that favors T regulatory cell responses. (Bach et al., 2004; Chen et al., 2009). NKT cells are protective in Chagas' disease (Duthie & Kahn, 2006; Olson et al., 2009) and IFNγ expression by the NKT cells appears to be crucial to their protective effect. Similarly, treating CVB3 infected mice with αGalCer is protective, again indicating a role for NKT cells in preventing myocarditis (Wu et al., 2010). However, whether these NKT cells also suppress immunopathogenicity by enhancing Treg cell responses is not clear. γδ T cells appear to have the opposite effect on Treg cell responses. IL-23 activated γδ cells prevent conversion of effector T cells to iTreg cells (Petermann et al., 2010). Similarly γδ cells reduce IL-10 producing Treg cells in the lung in an asthma model γδ cells (Hahn et al., 2008). Vγ2Vδ2 cells prevent IL-2 induced expansion of CD4+CD25+FoxP3+ T (Gong et al., 2009). γδ T cells promote dendritic cell maturation and enhance antigen presentation. Also, these innate effectors suppress IL-2 expression which is needed for Treg cell maintenance. Recently, it has been shown that CVB3-H3 infection of mice deficient in γδ cells results in significant increases in Treg cells and accumulation of a population of CD1d+ Treg cells (Huber, 2009, 2010). These CD1d+ Treg cells are substantially more immunosuppressive to myocarditis than the CD1d- Treg cells on a per cell basis. These CD1d+ Treg cells are absent in mice containing γδ cells, and adoptive transfer of activated γδ cells into CVB3-H3 infected γδKO mice both restores myocarditis susceptibility and eliminates the CD1d+ Treg cell population. Direct co-culture of the activated γδ cells on CD1d+ and CD1d- Treg cell populations shows that the γδ effector cells are lytic to the CD1d+ Treg in a CD1d- and caspase-dependent manner. (Huber, 2010).


Fig. 3. Cross-talk between innate effectors in control of adaptive immunity.

4. Conclusions

Innate immunity is the rapid host response and occurs within hours of microbial infections. Although a major role for innate immunity is to help dampen microbe replication until the adaptive immune response is adequately developed for final microbial elimination, another major role for innate immunity is to control and direct the developing adaptive immune response. There is substantial cross-talk between innate lymphocyte effectors during myocarditis. Both NKT and a population of γδ cells recognize CD1d, a non-classical MHC class I-like molecule. However, evidence implies that while NKT cells are protective in myocarditis, γδ cells are pro-inflammatory and pathogenic. Interesting similarities have been found in the role of NKT and γδ cells in two different myocarditis mouse models: CVB3 and Trypanosoma cruzi induced myocarditis. The fact that similar immune processes of pathogenicity and protection appear to function in these two models provides circumstantial evidence that these innate effectors may have identical roles in other forms of myocarditis and also in clinical disease. To date, little evidence actually exists for innate effectors in clinical disease. However, the strong association between microbial infections and myocarditis in humans means that innate immunity should be important.

5. Acknowledgements

6. References

Agaugue, S., Marcenaro, E., Ferranti, B., Moretta, L., and Moretta, A. (2008). Human natural killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells. *Blood,* Vol. 112 (September 2008), No. 5, pp. 1776-83, ISSN 0006-4971.

Alcami, A., and Koszinowski, U. (2000). Viral mechanisms of immune evasion. *Immunology Today,* Vol. 21 (September 2000), No. 9, pp. 447-455, ISSN 0167-5699.

Ambrosino, E., Terabe, M., Halder, R. C., Peng, J., Takaku, S., Miyake, S., Yamamura, T., Kumar, V., and Berzofsky, J. A. (2007). Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. *Journal of Immunology,* Vol. 179 (October 2007), No. 8, pp. 5126-36, ISSN 0022-1767.

Antoniou, A. N., and Powis, S. J. (2008). Pathogen evasion strategies for the major histocompatibility complex class I assembly pathway. *Immunology,* Vol. 124 (May, 2008), No. 1, pp. 1-12, ISSN 0019-2805.

Arase, H., Mocarski, E. S., Campbell, A. E., Hill, A. B., and Lanier, L. L. (2002). Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. *Science,* Vol. 296(May 2007), No. 5571, pp. 1323-6, ISSN 0193-4511.

Arrenberg, P., Halder, R., and Kumar, V. (2009). Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens. *Journal of Cellular Physiology,* Vol. 218 (February 2009), No. 2, pp. 246-50, ISSN 0021-9541.

Assier, E., Marin-Esteban, V., Haziot, A., Maggi, E., Charron, D., and Mooney, N. (2007). TLR7/8 agonists impair monocyte-derived dendritic cell differentiation and maturation. *Journal of Leukocyte Biology,* Vol. 81(January 2007), No. 1, pp. 221-8, ISSN 0741-5400.

Bach, J. F., Bendelac, A., Brenner, M. B., Cantor, H., De Libero, G., Kronenberg, M., Lanier, L. L., Raulet, D. H., Shlomchik, M. J., and von Herrath, M. G. (2004). The role of innate immunity in autoimmunity. The *Journal of Experimental Medicine,* Vol. 200 (December 2004), No.12, pp. 1527-31, ISSN 0022-1007.

Barral, D. C., and Brenner, M. B. (2007). CD1 antigen presentation: how it works. *Nature Reviews Immunology,* Vol. 7 (December 2007), No. 12, pp. 929-41, ISSN 1474-1733.

Beckman, E. M., Melian, A., Behar, S. M., Sieling, P. A., Chatterjee, D., Furlong, S. T., Matsumoto, R., Rosat, J. P., Modlin, R. L., and Porcelli, S. A. (1996). CD1c restricts responses of mycobacteria-specific T cells. Evidence for antigen presentation by a second member of the human CD1 family. *Journal of Immunology,* Vol. 157 (October 1996), No. 7, pp. 2795-803, ISSN 0022-1767.

Beckman, E. M., Porcelli, S. A., Morita, C. T., Behar, S. M., Furlong, S. T., and Brenner, M. B. (1994). Recognition of a lipid antigen by CD1-restricted alpha beta+ T cells. *Nature,* Vol. 372 (December 1994), No. 6507, pp. 691-4, ISSN 0028-0836.

Bendelac, A., Savage, P. B., and Teyton, L. (2007). The biology of NKT cells. *Annual Review of Immunology,* Vol. 25 (April 2007), pp.297-336, ISSN 0732-0582.

Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P., and Salazar-Mather, T. P. (1999). Natural killer cells in antiviral defense: function and regulation by innate cytokines. *Annual Review of Immunology,* Vol. 17 (April 199), pp. 189-220, ISSN 0732-0582.

Blumberg, R. S., Gerdes, D., Chott, A., Porcelli, S. A., and Balk, S. P. (1995). Structure and function of the CD1 family of MHC-like cell surface proteins. *Immunological Reviews,* Vol. 147 (October 1995), pp. 5-29, ISSN 0105-2896.

Boes, M., Stoppelenburg, A. J., and Sille, F. C. (2009). Endosomal processing for antigen presentation mediated by CD1 and Class I major histocompatibility complex: roads to display or destruction. *Immunology,* Vol. 127 (June 2009), No. 2, pp. 163-70, ISSN 0019-2805.

Bowles, N. E., Ni, J., Kearney, D. L., Pauschinger, M., Schultheiss, H. P., McCarthy, R., Hare, J., Bricker, J. T., Bowles, K. R., and Towbin, J. A. (2003). Detection of viruses in myocardial tissues by polymerase chain reaction. evidence of adenovirus as a common cause of myocarditis in children and adults. *Journal of American College of Cardiology,* Vol. 42 (August 2003), No. 3, pp. 466-72, ISSN 0735-1097.

Bradbury, A., Calabi, F., and Milstein, C. (1990). Expression of CD1 in the mouse thymus. *European Journal of Immunology,* Vol. 20 (August 1990), No. 8, pp. 1831-6, ISSN 0014-2980.

Brener, Z., and Gazzinelli, R. T. (1997). Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease. *International Archices of Allergy and Immunology,* Vol. 114 (October 1997), No. 2, pp. 103-10, ISSN 1018-2438.

Brigl, M., Bry, L., Kent, S. C., Gumperz, J. E., and Brenner, M. B. (2003). Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. *Nature Immunology,* Vol. 4 (December 2003), No. 12, pp. 1230-7, ISSN 1529-2908.

Brutkiewicz, R. R., Bennink, J. R., Yewdell, J. W., and Bendelac, A. (1995). TAP-independent, beta 2-microglobulin-dependent surface expression of functional mouse CD1.1. *The Journal of Experimental Medicine,* Vol. 182 (December 1995), No. 6, pp. 1913-9, ISSN 0022-1007.

Calabi, F., Jarvis, J. M., Martin, L., and Milstein, C. (1989). Two classes of CD1 genes. *European Journal of Immunology,* Vol. 19 (February 1989), No. 2, pp. 285-92, ISSN 0014-2980.

Cardell, S. L. (2006). The natural killer T lymphocyte: a player in the complex regulation of autoimmune diabetes in non-obese diabetic mice. *Clinical and Experimental Immunology,* Vol. 143 (February 2006), No. 2, pp. 194-202, ISSN 0009-9104.

Carnaud, C., Lee, D., Donnars, O., Park, S. H., Beavis, A., Koezuka, Y., and Bendelac, A. (1999). Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. *Journal of Immunology,* Vol. 163 (November 1999), No. 9, pp. 4647-50, ISSN 0022-1767.

Chen, G., Han, G., Wang, J., Wang, R., Xu, R., Shen, B., Qian, J., and Li, Y. (2009). Natural killer cells modulate overt autoimmunity to homeostasis in nonobese diabetic mice after anti-CD3 F(ab')2 antibody treatment through secreting transforming growth factor-beta. *The American Journal of Pathology,* Vol. 175 (September 2009), No. 3, pp. 1086-94, ISSN 0002-9440.

Cheng, T. Y., Relloso, M., Van Rhijn, I., Young, D. C., Besra, G. S., Briken, V., Zajonc, D. M., Wilson, I. A., Porcelli, S., and Moody, D. B. (2006). Role of lipid trimming and CD1 groove size in cellular antigen presentation. *The EMBO Journal,* Vol. 25 (July 2006), No. 13, pp. 2989-99, ISSN 0261-4189.

Chien, Y. H., and Konigshofer, Y. (2007). Antigen recognition by gammadelta T cells. *Immunological Reviews,* Vol. 215 (February 2007), pp. 46-58, ISSN 0105-2896.

Chow, L. H., Ye, Y., Linder, J., and McManus, B. M. (1989). Phenotypic analysis of infiltrating cells in human myocarditis. An immunohistochemical study in paraffin-embedded tissue. *Archives of Pathology & Laboratory Medicine,* Vol. 113 (December 1989), No. 12, pp. 1357-62, ISSN 0003-9985.

Cui, Y., Kang, L., Cui, L., and He, W. (2009). Human gammadelta T cell recognition of lipid A is predominately presented by CD1b or CD1c on dendritic cells. *Biology Direct,* Vol. 4 (December 2009), pp. 47, ISSN 1745-6150.

Darmoise, A., Teneberg, S., Bouzonville, L., Brady, R. O., Beck, M., Kaufmann, S. H., and Winau, F. (2010). Lysosomal alpha-galactosidase controls the generation of self lipid antigens for natural killer T cells. *Immunity,* Vol. 33 (August 2010), No. 2, pp. 216-28, ISSN 1074-7613.

Das, H., Sugita, M., and Brenner, M. B. (2004). Mechanisms of Vdelta1 gammadelta T cell activation by microbial components. *Journal of Immunology,* Vol. 172 (June 2004), No. 11, pp. 6578-86, ISSN 0022-1767.

de la Salle, H., Mariotti, S., Angenieux, C., Gilleron, M., Garcia-Alles, L. F., Malm, D., Berg, T., Paoletti, S., Maitre, B., Mourey, L., Salamero, J., Cazenave, J. P., Hanau, D., Mori, L., Puzo, G., and De Libero, G. (2005). Assistance of microbial glycolipid antigen processing by CD1e. *Science,* Vol. 310 (November 2005), No. 5752, pp. 1321-4, ISSN 0193-4511.

De Libero, G., Moran, A. P., Gober, H. J., Rossy, E., Shamshiev, A., Chelnokova, O., Mazorra, Z., Vendetti, S., Sacchi, A., Prendergast, M. M., Sansano, S., Tonevitsky, A., Landmann, R., and Mori, L. (2005). Bacterial infections promote T cell recognition of self-glycolipids. *Immunity,* Vol. 22 (June 2005), No. 6, pp. 763-72, ISSN 1074-7613.

De Libero, G., and Mori, L. (2003). Self glycosphingolipids: new antigens recognized by autoreactive T lymphocytes. *News in Physiological Sciences,* Vol. 18 (April 2003), pp. 71-6, ISSN 0886-1714.

De Santo, C., Salio, M., Masri, S. H., Lee, L. Y., Dong, T., Speak, A. O., Porubsky, S., Booth, S., Veerapen, N., Besra, G. S., Grone, H. J., Platt, F. M., Zambon, M., and Cerundolo, V. (2008). Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. *The Journal of Clinical Investigation*, Vol 118 (December 2008), No. 12, pp. 4036-48, ISSN 0021-9738.

Donovan, M. J., Jayakumar, A., and McDowell, M. A. (2007). Inhibition of groups 1 and 2 CD1 molecules on human dendritic cells by Leishmania species. *Parasite Immunology*, Vol. 29 (October 2007), No. 10, pp. 515-24, ISSN 0141-9838.

dos Santos, P. V., Roffe, E., Santiago, H. C., Torres, R. A., Marino, A. P., Paiva, C. N., Silva, A. A., Gazzinelli, R. T., and Lannes-Vieira, J. (2001). Prevalence of CD8(+)alpha beta T cells in Trypanosoma cruzi-elicited myocarditis is associated with acquisition of CD62L(Low)LFA-1(High)VLA-4(High) activation phenotype and expression of IFN-gamma-inducible adhesion and chemoattractant molecules. *Microbes and Infection*, Vol. 3 (October 2001), No. 12, pp. 971-84, ISSN 1286-4579.

Dougan, S. K., Kaser, A., and Blumberg, R. S. (2007). CD1 expression on antigen-presenting cells. *Current Topics in Microbiology and Immunology*, Vol. 314, pp. 113-41, ISSN 0070-217X.

Duarte, N., Stenstrom, M., Campino, S., Bergman, M. L., Lundholm, M., Holmberg, D., and Cardell, S. L. (2004). Prevention of diabetes in nonobese diabetic mice mediated by CD1d-restricted nonclassical NKT cells. *Journal of Immunology*, Vol. 173 (September 2004), No. 5, pp. 3112-8, ISSN 0022-1767.

Durante-Mangoni, E., Wang, R., Shaulov, A., He, Q., Nasser, I., Afdhal, N., Koziel, M. J., and Exley, M. A. (2004). Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells. *Journal of Immunology*, Vol. 173 (August 2004), No. 3, pp. 2159-66, ISSN 0022-1767.

Duthie, M. S., and Kahn, S. J. (2006). During acute Trypanosoma cruzi infection highly susceptible mice deficient in natural killer cells are protected by a single alpha-galactosylceramide treatment. *Immunology*, Vol. 119 (November 2006), No. 3, pp. 355-61, ISSN 0019-2805.

Dvir, H., Wang, J., Ly, N., Dascher, C. C., and Zajonc, D. M. (2010). Structural basis for lipid-antigen recognition in avian immunity. *Journal of Immunology*, Vol. 184 (March 2010), No. 5, pp. 2504-11, ISSN 0022-1767.

Eck, M., Greiner, A., Kandolf, R., Schmausser, B., Marx, A., and Muller-Hermelink, H. K. (1997). Active fulminant myocarditis characterized by T-lymphocytes expressing the gamma-delta T-cell receptor: a new disease entity? The *American Journal of Surgical Pathology*, Vol. 21 (September 1997), No. 9, pp. 1109-12, ISSN 0147-5185.

Eckart, R. E., Scoville, S. L., Campbell, C. L., Shry, E. A., Stajduhar, K. C., Potter, R. N., Pearse, L. A., and Virmani, R. (2004). Sudden death in young adults: a 25-year review of autopsies in military recruits. *Annals of Internal Medicine*, Vol. 141 (December 2004), No. 11, pp. 829-34, ISSN 0003-4819.

Exley, M., Bigley, N., Cheng, O., Tahir, S., Smiley, S., Carter, Q., Stills, H., Grusby, M., Koezuka, Y., Taniguchi, M., and Balk, S. (2001). CD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus. *Journal of Leukocyte Biology*, Vol. 69 (May 2001), No. 5, pp. 713-718, ISSN 0741-5400.

Fabre A, S. M. (2006). Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death: a UK experience. *Heart,* Vol. 92 (March 2006), No. 3, pp. 316-320, ISSN 1355-6037.

Flodstrom-Tullberg, M., Bryceson, Y. T., Shi, F. D., Hoglund, P., and Ljunggren, H. G. (2009). Natural killer cells in human autoimmunity. *Current Opinion in Immunology,* Vol. 21 (December 2009), No. 6, pp. 634-40, ISSN 0952-7915.

Franchini, L., Matto, P., Ronchetti, F., Panza, L., Barbieri, L., Costantino, V., Mangoni, A., Cavallari, M., Mori, L., and De Libero, G. (2007). Synthesis and evaluation of human T cell stimulating activity of an alpha-sulfatide analogue. *Bioorganic & Medicinal Chemistry* Vol. 15 (August 2007), No. 16, pp. 5529-36, ISSN 0968-0896.

Friman, G., Wesslen, L., Fohlman, J., Karjalainen, J., and Rolf, C. (1995). The epidemiology of infectious myocarditis, lymphocytic and dilated cardiomyopathy. *European Heart Journal,* Vol. 16 (December 1995), No. Suppl o, pp. 36-41, ISSN 0195-668X.

Frisancho-Kiss, S., Nyland, J. F., Davis, S. E., Barrett, M. A., Gatewood, S. J., Njoku, D. B., Cihakova, D., Silbergeld, E. K., Rose, N. R., and Fairweather, D. (2006). Cutting edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity. *Journal of Immunology,* Vol. 176 (June 2006), No. 11, pp. 6411-5, ISSN 0022-1767.

Gauntt, C., Godney, E., and Lutton, C. (1988). Host factors regulating viral clearance. *Pathology and Immunopathology Research,* Vol. 7, pp. 251-265, ISSN 0257-2761.

Gauntt, C., Godney, E., Lutton, C., and Fernandes, G. (1989). Role of natural killer cells in experimental murine myocarditis. *Springer Seminars in Immunopathology,* Vol. 11, pp. 51-59, ISSN 0344-4325.

Gong, G., Shao, L., Wang, Y., Chen, C. Y., Huang, D., Yao, S., Zhan, X., Sicard, H., Wang, R., and Chen, Z. W. (2009). Phosphoantigen-activated V gamma 2V delta 2 T cells antagonize IL-2-induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infection. *Blood,* Vol. 113 (January 2009), No. 4, pp. 837-45, ISSN 0006-4971.

Guthrie, M., Lodge, P. A., and Huber, S. A. (1984). Cardiac injury in myocarditis induced by Coxsackievirus group B, type 3 in Balb/c mice is mediated by Lyt 2 + cytolytic lymphocytes. *Cellular Immunology,* Vol. 88 (October 1984), No. 2, pp. 558-67, ISSN 0008-8749.

Hage, C. A., Kohli, L. L., Cho, S., Brutkiewicz, R. R., Twigg, H. L., 3rd, and Knox, K. S. (2005). Human immunodeficiency virus gp120 downregulates CD1d cell surface expression. *Immunology Letters,* Vol. 98 (April 2005), No. 1, pp. 131-5, ISSN 0165-2478.

Hahn, Y. S., Ji, X. Y., Woo, S. I., Choi, Y. K., Song, M. S., Shin, K. S., Jin, N., O'Brien, R. L., and Born, W. K. (2008). Vgamma1+ gammadelta T cells reduce IL-10-producing CD4+CD25+ T cells in the lung of ovalbumin-sensitized and challenged mice. *Immunology Letters,* Vol. 121 (December 2008), No. 2, pp. 87-92, ISSN 0165-2478.

Halder, R. C., Aguilera, C., Maricic, I., and Kumar, V. (2007). Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. *The Journal of Clinical Investigation,* Vol. 117 (August 2007), No. 8, pp. 2302-12, ISSN 0021-9738.

Hegde, S., Fox, L., Wang, X., and Gumperz, J. E. (2010). Autoreactive natural killer T cells: promoting immune protection and immune tolerance through varied interactions with myeloid antigen-presenting cells. *Immunology,* Vol. 130 (August 2010), No. 4, pp. 471-83, ISSN 0019-2805.

Henke, A., Huber, S., Stelzner, A., and Whitton, J. (1995). The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis. *Journal of Virology*, Vol. 69 (November 1995), No. 11, pp. 6720-6728, ISSN 0022-538X.

Hewitt, E. W. (2003). The MHC class I antigen presentation pathway: strategies for viral immune evasion. *Immunology*, Vol. 110 (October 2003), No. 2, pp.163-9, ISSN 1365-2567.

Hosoi, T., Suzuki, S., Nomura, J., Ono, A., Okuma, Y., Akira, S., and Nomura, Y. (2004). Bacterial DNA induced iNOS expression through MyD88-p38 MAP kinase in mouse primary cultured glial cells. *Brain Research Molecular Brain Research*, Vol. 124 (May 2004), No. 2, pp. 159-64, ISSN 0169-328X.

Huber, S. (2000). T cells expressing the gamma-delta T cell receptor induce apoptosis in cardiac myocytes. *Cardiovascular Research*, Vol. 45 (February 2000), No. 3, pp. 579-587, ISSN 0008-6363.

Huber, S. (2010). γδ T lymphocytes kill T regulatory cells through CD1d. *Immunology*, Vol. 131 (October 2010), No. 2, pp. 202-209, ISSN 0019-2805.

Huber, S., and Gauntt, C. (2000). Antigenic mimicry between self and coxsackievirus protein leads to both humoral and cellular autoimmunity to heart proteins, In: *Molecular Mimicry in Disease*, M. Cunningham and R. Fijinami, pp. 51, ASM Press, ISBN 1555811949, Washington DC.

Huber, S., and Lodge, P. (1984). Coxsackievirus B3 myocarditis in Balb/c mice: evidence for autoimmunity to myocyte antigens. *The American Journal of Pathology*, Vol. 116 (July 1984), No. 1, pp. 21-9, ISSN 0002-9440.

Huber, S., Lodge, P., Herzum, M., Estrin, M., and Olszewski, J. (1987). The role of T lymphocytes in the pathogenesis of coxsackievirus B3 myocarditis, In: *Cardiomyopathy Update 1: Pathogenesis of Myocarditis and Cardiomyopathy*, C. Kawai, W. Abelmann and A. Matsumori, pp. 9-21. University of Tokyo Press, ISBN 0860084191, Tokyo Japan.

Huber, S., and Sartini, D. (2005a). T cells expressing the Vgamma1 T-cell receptor enhance virus-neutralizing antibody response during coxsackievirus B3 infection of BALB/c mice: differences in male and female mice. *Viral Immunology*, Vol. 18, No. 4, pp. 730-9, ISSN 0882-8245.

Huber, S., Sartini, D., and Exley, M. (2003). Role of CD1d in coxsackievirus B3-induced myocarditis. *Journal of Immunology*, Vol. 170 (March 2003), No. 6, pp. 3147-53 (ISSN 0022-1767).

Huber, S., Shi, C., and Budd, R. C. (2002). Gammadelta T cells promote a Th1 response during coxsackievirus B3 infection in vivo: role of Fas and Fas ligand. *Journal of Virology*, Vol. 76 (July 2002), No. 13, pp. 6487-94, ISSN 0022-538X.

Huber, S., Weller, A., Herzum, M., Lodge, P., Estrin, M., Simpson, K., and Guthrie, M. (1988). Immunopathogenic mechanisms in experimental picornavirus-induced autoimmunity. *Pathology and Immunopathology Research*, Vol. 7, No. 4, pp. 279-91, ISSN 0257-2761.

Huber, S. A. (2006). CD1d expression on hemopoietic cells promotes CD4+ Th1 response in coxsackievirus B3 induced myocarditis. *Virology*, Vol. 352 (August 2006), No. 1, pp. 226-36, ISSN 0042-6822.

Huber, S. A. (2009). Depletion of gammadelta+ T cells increases CD4+ FoxP3 (T regulatory) cell response in coxsackievirus B3-induced myocarditis. *Immunology*, Vol. 127 (August 2009), No. 4, pp. 567-76, ISSN 0019-2805.

Huber, S. A., Feldman, A. M., and Sartini, D. (2006). Coxsackievirus B3 induces T regulatory cells, which inhibit cardiomyopathy in tumor necrosis factor-alpha transgenic mice. *Circulation Research,* Vol. 99 (November 2006), No. 10, pp. 1109-16, ISSN 0009-7330.

Huber, S. A., and Sartini, D. (2005b). Roles of tumor necrosis factor alpha (TNF-alpha) and the p55 TNF receptor in CD1d induction and coxsackievirus B3-induced myocarditis. *Journal of Virology,* Vol. 79 (March 2005), No. 5, pp. 2659-65, ISSN 0022-538X.

Huber, S. A., Sartini, D., and Exley, M. (2002). Vgamma4(+) T cells promote autoimmune CD8(+) cytolytic T-lymphocyte activation in coxsackievirus B3-induced myocarditis in mice: role for CD4(+) Th1 cells. *Journal of Virology,* Vol. 76 (November 2002), No. 21, pp. 10785-90, ISSN 0022-538X.

Jahng, A., Maricic, I., Aguilera, C., Cardell, S., Halder, R. C., and Kumar, V. (2004). Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. *The Journal of Experimental Medicine,* Vol. 199 (April 2004), No. 7, pp. 947-57, ISSN 0022-1007.

Jarahian, M., Watzl, C., Fournier, P., Arnold, A., Djandji, D., Zahedi, S., Cerwenka, A., Paschen, A., Schirrmacher, V., and Momburg, F. (2009). Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. *Journal of Virology,* Vol. 83 (August 2009), No. 16, pp. 8108-21.

Kasmar, A., Van Rhijn, I., and Moody, D. B. (2009). The evolved functions of CD1 during infection. *Current Opinion in Immunology,* Vol. 21 (August 2009), No. 4, pp. 397-403, ISSN 0952-7915.

Kaufmann, S. H. (1996). gamma/delta and other unconventional T lymphocytes: what do they see and what do they do? *Proceedings of the National Academy of Sciences of the United States of America,* Vol. 93 (March 1996), No. 6, pp. 2272-9, ISSN 0027-8424.

Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Motoki, K., Ueno, H., Nakagawa, R., Sato, H., Kondo, E., Koseki, H., and Taniguchi, M. (1997). CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. *Science,* Vol. 278 (November 1997), No. 5343, pp. 1626-9, ISSN 0193-4511.

Khovidhunkit, W., Kim, M. S., Memon, R. A., Shigenaga, J. K., Moser, A. H., Feingold, K. R., and Grunfeld, C. (2004). Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. *Journal of Lipid Research,* Vol. 45 (July 2004), No. 7, pp. 1169-96, ISSN 0022-2275.

Kielczewska, A., Pyzik, M., Sun, T., Krmpotic, A., Lodoen, M. B., Munks, M. W., Babic, M., Hill, A. B., Koszinowski, U. H., Jonjic, S., Lanier, L. L., and Vidal, S. M. (2009). Ly49P recognition of cytomegalovirus-infected cells expressing H2-Dk and CMV-encoded m04 correlates with the NK cell antiviral response. *The Journal of Experimental Medicine,* Vol. 206 (March 2009), No. 3, pp. 515-23, ISSN 0022-1007.

Kinjo, Y., Pei, B., Bufali, S., Raju, R., Richardson, S. K., Imamura, M., Fujio, M., Wu, D., Khurana, A., Kawahara, K., Wong, C. H., Howell, A. R., Seeberger, P. H., and Kronenberg, M. (2008). Natural Sphingomonas glycolipids vary greatly in their ability to activate natural killer T cells. *Chemistry & Biology,* Vol. 15 (July 2008), No. 7, pp. 654-64, ISSN 1074-5521.

Kinjo, Y., Tupin, E., Wu, D., Fujio, M., Garcia-Navarro, R., Benhnia, M. R., Zajonc, D. M., Ben-Menachem, G., Ainge, G. D., Painter, G. F., Khurana, A., Hoebe, K., Behar, S. M., Beutler, B., Wilson, I. A., Tsuji, M., Sellati, T. J., Wong, C. H., and Kronenberg, M. (2006). Natural killer T cells recognize diacylglycerol antigens from pathogenic

bacteria. *Nature Immunology,* Vol. 7 (September 2006), No. 9, pp. 978-86, ISSN 1529-2908.

Kinjo, Y., Wu, D., Kim, G., Xing, G. W., Poles, M. A., Ho, D. D., Tsuji, M., Kawahara, K., Wong, C. H., and Kronenberg, M. (2005). Recognition of bacterial glycosphingolipids by natural killer T cells. *Nature,* Vol. 434 (March 2005), No. 7032, pp. 520-5, ISSN 0028-0836.

Knowlton, K. U., Jeon, E. S., Berkley, N., Wessely, R., and Huber, S. (1996). A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. *Journal of Virology,* Vol. 70 (November 1996), No. 11, pp. 7811-8, ISSN 0022-538X.

Krawczyk, C. M., Shen, H., and Pearce, E. J. (2007). Memory CD4 T cells enhance primary CD8 T-cell responses. *Infection and Immunity,* Vol. 75 (July 2007), No. 7, pp. 3556-60, ISSN 0019-9567.

Kronenberg, M. (2005). Toward an understanding of NKT cell biology: progress and paradoxes. *Annual Review of Immunology,* Vol. 23 (January 2005), pp. 877-900, ISSN 0732-0582.

Kulkarni RR, H. S., Sharif S. (2010). The invariant NKT cell subset in anti-viral defenses: a dark horse in anti-influenza immunity? *Journal of Leukocyte Biology, Vol.* 88 (October 2010), No. 4, pp. 635-43, ISSN 0741-5400.

Kumanogoh, A., Wang, X., Lee, I., Watanabe, C., Kamanaka, M., Shi, W., Yoshida, K., Sato, T., Habu, S., Itoh, M., Sakaguchi, N., Sakaguchi, S., and Kikutani, H. (2001). Increased T cell autoreactivity in the absence of CD40-CD40 ligand interactions: a role of CD40 in regulatory T cell development. *Journal of Immunology.* Vol. 166 (January 2001), No. 1, pp. 353-60, ISSN 0022-1767.

La Cava, A., Van Kaer, L., and Fu Dong, S. (2006). CD4+CD25+ Tregs and NKT cells: regulators regulating regulators. *Trends in Immunology,* Vol. 27 (July 2006), No. 7, pp. 322-7, ISSN 1471-4906.

Lanier, L. L. (2008). Up on the tightrope: natural killer cell activation and inhibition. *Nature Immunology,* Vol. 9 (May 2008), No. 5, pp. 495-502, ISSN 1529-2908.

Leslie, D. S., Dascher, C. C., Cembrola, K., Townes, M. A., Hava, D. L., Hugendubler, L. C., Mueller, E., Fox, L., Roura-Mir, C., Moody, D. B., Vincent, M. S., Gumperz, J. E., Illarionov, P. A., Besra, G. S., Reynolds, C. G., and Brenner, M. B. (2008). Serum lipids regulate dendritic cell CD1 expression and function. *Immunology,* Vol. 125 (November 2008), No. 3, pp. 289-301, ISSN 0019-2805.

Li, D., and Xu, X. N. (2008). NKT cells in HIV-1 infection. *Cell Research,* Vol. 18 (August 2008), No. 8, pp. 817-22, ISSN 1001-0602.

Liu W, L. W., Gao C, Sun NL (2005). Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats. . *Journal of Autoimmunity,* Vol. 25 (December 2005), No. 4, pp. 258-263, ISSN 0896-8411.

Lohoff, M., Duncan, G. S., Ferrick, D., Mittrucker, H. W., Bischof, S., Prechtl, S., Rollinghoff, M., Schmitt, E., Pahl, A., and Mak, T. W. (2000). Deficiency in the transcription factor interferon regulatory factor (IRF)-2 leads to severely compromised development of natural killer and T helper type 1 cells. *The Journal of Experimental Medicine,* Vol. 192 (August 2000), No. 3, pp. 325-36, ISSN 0022-1007.

Lunemann, A., Lunemann, J. D., and Munz, C. (2009). Regulatory NK-cell functions in inflammation and autoimmunity. *Molecular Medicine,* Vol. 15 (September-October 2009), No. 9-10, pp. 352-8, ISSN 1076-1551.

Ly, D., Mi, Q. S., Hussain, S., and Delovitch, T. L. (2006). Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4+CD25+ regulatory T cells. *Journal of Immunology,* Vol. 177 (September 2006), No. 6, pp. 3695-704, ISSN 0022-1767.

Maisch, B., Bulowius, U., Schmier, K., Klopf , D., Koper, D., Sivelis, T., and Kochsiek, K. (1985). Immunological cellular regulator and effector mechanisms in myocarditis. *Herz,* Vol. 10 (February 1985), No. 1, pp. 8-14, ISSN 0340-9937.

Malek, T. R., and Bayer, A. L. (2004). Tolerance, not immunity, crucially depends on IL-2. *Nature Reviews Immunology, Vol.* 4 (September 2004), No. 9, pp. 665-74, ISSN 1474-1733.

Mandelboim, O., Lieberman, N., Lev, M., Paul, L., Arnon, T. I., Bushkin, Y., Davis, D. M., Strominger, J. L., Yewdell, J. W., and Porgador, A. (2001). Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. *Nature,* Vol. 409 (February 2001), No. 6823, pp.1055-60, ISSN 0028-0836.

Mantel, P. Y., and Schmidt-Weber, C. B. (2010). Transforming growth factor-beta: recent advances on its role in immune tolerance. *Methods in Molecular Biology,* Vol. 677, pp. 303-38, ISSN 1064-3745.

Marin-Neto, J. A., Cunha-Neto, E., Maciel, B. C., and Simoes, M. V. (2007). Pathogenesis of chronic Chagas heart disease. *Circulation,* Vol. 115 (March 2007), No. 9, pp. 1109-23, ISSN 0009-7322.

Mattner, J., Debord, K. L., Ismail, N., Goff, R. D., Cantu, C., 3rd, Zhou, D., Saint-Mezard, P., Wang, V., Gao, Y., Yin, N., Hoebe, K., Schneewind, O., Walker, D., Beutler, B., Teyton, L., Savage, P. B., and Bendelac, A. (2005). Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. *Nature,* Vol. 434 (March 2005), No. 7032, pp. 525-9, ISSN 0028-0836.

Mattner, J., Savage, P. B., Leung, P., Oertelt, S. S., Wang, V., Trivedi, O., Scanlon, S. T., Pendem, K., Teyton, L., Hart, J., Ridgway, W. M., Wicker, L. S., Gershwin, M. E., and Bendelac, A. (2008). Liver autoimmunity triggered by microbial activation of natural killer T cells. *Cell Host & Microbe,* Vol. 3 (May 2008), No. 5, pp. 304-15, ISSN 1931-3128.

McGuirk, P., and Mills, K. H. (2002). Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. *Trends in Immunology,* Vol. 23 (September 2002), No. 9, pp. 450-5, ISSN 1471-4906.

Michel ML, K. A., Paget C, Fujio M, Trottein F, Savage PB, Wong CH, Schneider E, Dy M, Leite-de-Moraes MC. (2007). Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. *The Journal of Experimental Medicine.,* Vol. 204 (May 2007), No. 5, pp. 995-1001, ISSN 0022-1007.

Michelsen, K. S., Doherty, T. M., Shah, P. K., and Arditi, M. (2004). TLR signaling: an emerging bridge from innate immunity to atherogenesis. *Journal of Immunology,* Vol. 173 (November 2004), No. 10, pp. 5901-7, ISSN 0022-1767.

Monteiro, M., Almeida, C. F., Caridade, M., Ribot, J. C., Duarte, J., Agua-Doce, A., Wollenberg, I., Silva-Santos, B., and Graca, L. (2010). Identification of regulatory Foxp3+ invariant NKT cells induced by TGF-beta. *Journal of Immunology,* Vol. 185 (August 2010), No. 4, pp. 2157-63, ISSN 0022-1767.

Monzon-Casanova, E., Steiniger, B., Schweigle, S., Clemen, H., Zdzieblo, D., Starick, L., Muller, I., Wang, C. R., Rhost, S., Cardell, S., Pyz, E., and Herrmann, T. (2010). CD1d expression in paneth cells and rat exocrine pancreas revealed by novel

monoclonal antibodies which differentially affect NKT cell activation. *PLoS One*, Vol. 5 (September 2010), No. 9, ISSN 1932-6203.

Moody, D. B. (2001). Polyisoprenyl glycolipids as targets of CD1-mediated T cell responses. *Cellular and Molecular Life Sciences*, Vol. 58 (September 2001), No. 10, pp. 1461-74, ISSN 1420-682X.

Moody, D. B. (2006). The surprising diversity of lipid antigens for CD1-restricted T cells. *Advances in Immunology*, Vol. 89, pp. 87-139, ISSN 0065-2776.

Nomizo, A., Cardillo, F., Postol, E., de Carvalho, L. P., and Mengel, J. (2006). V gamma 1 gammadelta T cells regulate type-1/type-2 immune responses and participate in the resistance to infection and development of heart inflammation in Trypanosoma cruzi-infected BALB/c mice. *Microbes & Infection*, Vol. 8 (March 2006), No. 3, pp. 880-8, ISSN 1286-4579.

Nowak, M., Kopp, F., Roelofs-Haarhuis, K., Wu, X., and Gleichmann, E. (2006). Oral nickel tolerance: Fas ligand-expressing invariant NK T cells promote tolerance induction by eliciting apoptotic death of antigen-carrying, effete B cells. *Journal of Immunology*, Vol. 176 (April 2006), No. 8, pp. 4581-9, ISSN 0022-1767.

O'Neill, L. A. (2004). TLRs: Professor Mechnikov, sit on your hat. *Trends in Immunology*, Vol. 25 (December 2004), No. 12, pp. 687-93, ISSN 1471-4906.

Odyniec, A., Szczepanik, M., Mycko, M. P., Stasiolek, M., Raine, C. S., and Selmaj, K. W. (2004). Gammadelta T cells enhance the expression of experimental autoimmune encephalomyelitis by promoting antigen presentation and IL-12 production. *Journal of Immunology*, Vol. 173 (July 2004), No. 1, pp. 682-94, ISSN 1754-1441.

Ogasawara, K., Hida, S., Azimi, N., Tagaya, Y., Sato, T., Yokochi-Fukuda, T., Waldmann, T. A., Taniguchi, T., and Taki, S. (1998). Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. *Nature*, Vol. 391 (February 1998), No. 6668, pp. 700-3, ISSN 0028-0836.

Olson, C. M., Jr., Bates, T. C., Izadi, H., Radolf, J. D., Huber, S. A., Boyson, J. E., and Anguita, J. (2009). Local production of IFN-gamma by invariant NKT cells modulates acute Lyme carditis. *Journal of Immunology*, Vol. 182 (March 2009), No. 6, pp. 3728-34, ISSN 0022-1767.

Orange, J. S., Fassett, M. S., Koopman, L. A., Boyson, J. E., and Strominger, J. L. (2002). Viral evasion of natural killer cells. *Nature Immunology*, Vol. 3 (November 2002), No. 11, pp. 1006-12, ISSN 1529-2908.

Ozdemir, C., Akdis, M., and Akdis, C. A. (2009). T regulatory cells and their counterparts: masters of immune regulation. *Clinical and Experimental Allergy*, Vol. 39 (May 2009), No. 5, pp. 626-39, ISSN 0954-7894.

Paget, C., Mallevaey, T., Speak, A. O., Torres, D., Fontaine, J., Sheehan, K. C., Capron, M., Ryffel, B., Faveeuw, C., Leite de Moraes, M., Platt, F., and Trottein, F. (2007). Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids. *Immunity*, Vol. 27 (October 2007), No. 4, pp. 597-609, ISSN 1074-7613.

Pei, B., Speak, A. O., Shepherd, D., Butters, T., Cerundolo, V., Platt, F. M., and Kronenberg, M. (2010). Diverse endogenous antigens for mouse NKT cells: self-antigens that are not glycosphingolipids. *Journal of Immunology*, Vol. 186 (February 2011), No. 3, pp. 1348-60, ISSN 0022-1767.

Petermann, F., Rothhammer, V., Claussen, M. C., Haas, J. D., Blanco, L. R., Heink, S., Prinz, I., Hemmer, B., Kuchroo, V. K., Oukka, M., and Korn, T. (2010). gammadelta T cells

enhance autoimmunity by restraining regulatory T cell responses via an interleukin-23-dependent mechanism. *Immunity,* Vol. 33 (September 2010), No. 3, pp. 351-63, ISSN 1074-7613.

Raftery, M. J., Winau, F., Kaufmann, S. H., Schaible, U. E., and Schonrich, G. (2006). CD1 antigen presentation by human dendritic cells as a target for herpes simplex virus immune evasion. *Journal of Immunology,* Vol. 177 (November 2006), No. 9, pp. 6207-14, ISSN 0022-1767.

Raghuraman, G., Geng, Y., and Wang, C. R. (2006). IFN-beta-mediated up-regulation of CD1d in bacteria-infected APCs. *Journal of Immunology,* Vol. 177 (December 2006), No. 11, pp. 7841-8, ISSN 0022-1767.

Ray, A., Khare, A., Krishnamoorthy, N., Qi, Z., and Ray, P. (2010). Regulatory T cells in many flavors control asthma. *Society for Mucosal Immunology,* Vol. 3 (May 2010), No. 3, pp. 216-29, ISSN 1933-0219.

Ribeiro-Dos-Santos, R., Mengel, J. O., Postol, E., Soares, R. A., Ferreira-Fernandez, E., Soares, M. B., and Pontes-De-Carvalho, L. C. (2001). A heart-specific CD4+ T-cell line obtained from a chronic chagasic mouse induces carditis in heart-immunized mice and rejection of normal heart transplants in the absence of Trypanosoma cruzi. *Parasite Immunology,* Vol. 23 (February 2001), No. 2, pp. 93-101, ISSN 0141-9838.

Rincon-Orozco, B., Kunzmann, V., Wrobel, P., Kabelitz, D., Steinle, A., and Herrmann, T. (2005). Activation of V gamma 9V delta 2 T cells by NKG2D. *Journal of Immunology,* Vol. 175 (August 2005), No. 4, pp. 2144-51, ISSN 0022-1767.

Roelofs-Haarhuis, K., Wu, X., and Gleichmann, E. (2004). Oral tolerance to nickel requires CD4+ invariant NKT cells for the infectious spread of tolerance and the induction of specific regulatory T cells. *Journal of Immunology,* Vol. 173 (July 2004), No. 2, pp.1043-50, ISSN 0022-1767.

Roelofs-Haarhuis, K., Wu, X., Nowak, M., Fang, M., Artik, S., and Gleichmann, E. (2003). Infectious nickel tolerance: a reciprocal interplay of tolerogenic APCs and T suppressor cells that is driven by immunization. *Journal of Immunology,* Vol. 171 (September 2003), No. 6, pp. 2863-72, ISSN 0022-1767.

Ronchi, F., and Falcone, M. (2008). Immune regulation by invariant NKT cells in autoimmunity. *Frontiers in Bioscience,* Vol. 13 (May 2008), pp. 4827-37, ISSN 1945-0494.

Roura-Mir, C., Wang, L., Cheng, T. Y., Matsunaga, I., Dascher, C. C., Peng, S. L., Fenton, M. J., Kirschning, C., and Moody, D. B. (2005). Mycobacterium tuberculosis regulates CD1 antigen presentation pathways through TLR-2. *Journal of Immunology,* Vol. 175 (August 2005), No. 3, pp. 1758-66, ISSN 0022-1767.

Roy, K. C., Maricic, I., Khurana, A., Smith, T. R., Halder, R. C., and Kumar, V. (2008). Involvement of secretory and endosomal compartments in presentation of an exogenous self-glycolipid to type II NKT cells. *Journal of Immunology,* Vol. 180 (March 2008), No. 5, pp. 2942-50, ISSN 0022-1767.

Russano, A. M., Bassotti, G., Agea, E., Bistoni, O., Mazzocchi, A., Morelli, A., Porcelli, S. A., and Spinozzi, F. (2007). CD1-restricted recognition of exogenous and self-lipid antigens by duodenal gammadelta+ T lymphocytes. *Journal of Immunology,* Vol. 178 (March 2007), No. 6, pp. 3620-6, ISSN 0022-1767.

Sakaguchi, S. (2005). Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. *Nature Immunology,* Vol. 6 (April 2005), No. 4, pp. 345-52, ISSN 1529-2908.

Sakaguchi, S., Yamaguchi, T., Nomura, T., and Ono, M. (2008). Regulatory T cells and immune tolerance. *Cell,* Vol. 133 (May 2008), No. 5, pp. 775-87.

Salio, M., Speak, A. O., Shepherd, D., Polzella, P., Illarionov, P. A., Veerapen, N., Besra, G. S., Platt, F. M., and Cerundolo, V. (2007). Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation. *Proceedings of the National Academy of Sciences of the United States of America,* Vol. 104 (December 2007), No. 51, pp. 20490-5, ISSN 0027-8424.

Sallusto, F., and Lanzavecchia, A. (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. *The Journal of Experimental Medicine,* Vol. 179 (April 1994), No. 4, pp. 1109-18, ISSN 0022-1007.

Salomon, B., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A., and Bluestone, J. A. (2000). B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. *Immunity,* Vol. 12 (April 2000), No. 4, pp. 431-40, ISSN 1074-7613.

Sanchez, D. J., Gumperz, J. E., and Ganem, D. (2005). Regulation of CD1d expression and function by a herpesvirus infection. *The Journal of Clinical Investigation,* Vol. 115 (May 2005), No. 5, pp. 1369-78, ISSN 0021-9738.

Sathler-Avelar, R., Lemos, E. M., Reis, D. D., Medrano-Mercado, N., Araujo-Jorge, T. C., Antas, P. R., Correa-Oliveira, R., Teixeira-Carvalho, A., Eloi-Santos, S. M., Favato, D., and Martins-Filho, O. A. (2003). Phenotypic features of peripheral blood leucocytes during early stages of human infection with Trypanosoma cruzi. *Scandinavian Journal of Immunology,* Vol. 58 (December 2003), No. 6, pp. 655-63, ISSN 0300-9475.

Serre, K., Giraudo, L., Siret, C., Leserman, L., and Machy, P. (2006). CD4 T cell help is required for primary CD8 T cell responses to vesicular antigen delivered to dendritic cells in vivo. *European Journal of Immunology,* Vol. 36 (June 2006), No. 6, pp. 1386-97, ISSN 0014-2980.

Shamshiev, A., Donda, A., Prigozy, T. I., Mori, L., Chigorno, V., Benedict, C. A., Kappos, L., Sonnino, S., Kronenberg, M., and De Libero, G. (2000). The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. *Immunity,* Vol. 13 (August 2000), No. 2, pp. 255-64, ISSN 1074-7613.

Sieling, P. A., Chatterjee, D., Porcelli, S. A., Prigozy, T. I., Mazzaccaro, R. J., Soriano, T., Bloom, B. R., Brenner, M. B., Kronenberg, M., Brennan, P. J., and et al. (1995). CD1-restricted T cell recognition of microbial lipoglycan antigens. *Science,* Vol. 269 (July 1995), No. 5221, pp. 227-30, ISSN 0193-4511.

Sikder, H., Zhao, Y., Balato, A., Chapoval, A., Fishelevich, R., Gade, P., Singh, I. S., Kalvakolanu, D. V., Johnson, P. F., and Gaspari, A. A. (2009). A central role for transcription factor C/EBP-beta in regulating CD1d gene expression in human keratinocytes. *Journal of Immunology,* Vol. 183 (August 2009), No. 3, pp. 1657-66, ISSN 0022-1767.

Skold, M., and Behar, S. M. (2003). Role of CD1d-restricted NKT cells in microbial immunity. *Infection and Immunity.* Vol. 71 (October 2003), No. 10, pp. 5447-55, ISSN 0019-9567.

Skold, M., Xiong, X., Illarionov, P. A., Besra, G. S., and Behar, S. M. (2005). Interplay of cytokines and microbial signals in regulation of CD1d expression and NKT cell

activation. *Journal of Immunology,* Vol. 175 (July 2005), No. 6, pp. 3584-93, ISSN 0022-1767.

Smed-Sorensen, A., Moll, M., Cheng, T. Y., Lore, K., Norlin, A. C., Perbeck, L., Moody, D. B., Spetz, A. L., and Sandberg, J. K. (2008). IgG regulates the CD1 expression profile and lipid antigen-presenting function in human dendritic cells via FcgammaRIIa. *Blood,* Vol. 111 (May 2008), No. 10, pp. 5037-46, ISSN 0006-4971.

Soares, M. B., Silva-Mota, K. N., Lima, R. S., Bellintani, M. C., Pontes-de-Carvalho, L., and Ribeiro-dos-Santos, R. (2001). Modulation of chagasic cardiomyopathy by interleukin-4: dissociation between inflammation and tissue parasitism. *The American Journal of Pathology,* Vol. 159 (August 2001), No. 2, pp. 703-9, ISSN 0002-9440.

Solberg, E. E., Gjertsen, F., Haugstad, E., and Kolsrud, L. (2010). Sudden death in sports among young adults in Norway. *European Journal of Cardiovascular Prevention and Rehabilitation,* Vol. 17 (June 2010), No. 3, pp. 337-41, ISSN 1741-8267.

Sonoda, K. H., Exley, M., Snapper, S., Balk, S. P., and Stein-Streilein, J. (1999). CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. *The Journal of Experimental Medicine,* Vol. 190 (November 1999), No. 9, pp. 1215-26, ISSN 0022-1007.

Sonoda, K. H., Faunce, D. E., Taniguchi, M., Exley, M., Balk, S., and Stein-Streilein, J. (2001). NK T cell-derived IL-10 is essential for the differentiation of antigen-specific T regulatory cells in systemic tolerance. *Journal of Immunology,* Vol. 166 (January 2001), No. 1, pp. 42-50, ISSN 0022-1767.

Spada, F. M., Grant, E. P., Peters, P. J., Sugita, M., Melian, A., Leslie, D. S., Lee, H. K., van Donselaar, E., Hanson, D. A., Krensky, A. M., Majdic, O., Porcelli, S. A., Morita, C. T., and Brenner, M. B. (2000). Self-recognition of CD1 by gamma/delta T cells: implications for innate immunity. *The Journal of Experimental Medicine*, Vol. 191 (March 2000), No. 6, pp. 937-48, ISSN 0022-1007.

Stein-Streilein, J., Sonoda, K. H., Faunce, D., and Zhang-Hoover, J. (2000). Regulation of adaptive immune responses by innate cells expressing NK markers and antigen-transporting macrophages. *Journal of Leukocyte Biology,* Vol. 67 (April 2000), No. 4, pp. 488-94, ISSN 0741-5400.

Stetson, D. B., Mohrs, M., Reinhardt, R. L., Baron, J. L., Wang, Z. E., Gapin, L., Kronenberg, M., and Locksley, R. M. (2003). Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. *The Journal of Experimental Medicine,* Vol. 198 (October 2003), No. 7, pp. 1069-76, ISSN 0022-1007

Sugita, M., Grant, E. P., van Donselaar, E., Hsu, V. W., Rogers, R. A., Peters, P. J., and Brenner, M. B. (1999). Separate pathways for antigen presentation by CD1 molecules. *Immunity,* Vol. 11 (December 1999), No. 6, pp. 743-52, ISSN 1074-7613.

Szalay, G., Sauter, M., Hald, J., Weinzierl, A., Kandolf, R., and Klingel, K. (2006). Sustained nitric oxide synthesis contributes to immunopathology in ongoing myocarditis attributable to interleukin-10 disorders. The *American Journal of Pathology,* Vol. 169 (December 2006), No. 6, pp. 2085-93, ISSN 0002-9440.

Takeda, N., Seko, Y., Oriuchi, N., and Nagai, R. (2008). Gamma-delta T-cell-mediated dilated cardiomyopathy. *International Journal of Cardiology,* Vol. 125 (March 2008), No. 1, pp. 130-2, ISSN 0167-5273.

Takeda, N., Takahashi, T., Seko, Y., Maemura, K., Nakasone, H., Sakamoto, K., Hirata, Y., and Nagai, R. (2005). Takayasu myocarditis mediated by cytotoxic T lymphocytes. *Internal Medicine,* Vol. 44 (March 2005), No. 3, pp. 256-60, ISSN 0918-2918.

Taniguchi, M., Tashiro, T., Dashtsoodol, N., Hongo, N., and Watarai, H. (2010). The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy. *International Immunology,* Vol. 22 (January 2010), No. 1, pp. 1-6, ISSN 0953-8178.

Taniguchi, T., Ogasawara, K., Takaoka, A., and Tanaka, N. (2001). IRF family of transcription factors as regulators of host defense. *Annual Review of Immunology,* Vol. 19 (April 2001), pp. 623-55, ISSN 0732-0582.

Terabe, M., and Berzofsky, J. A. (2008). The role of NKT cells in tumor immunity. *Advances in Cancer Research,* Vol. 101(December 2008), pp. 277-348, ISSN 0065-230X.

Topham, N. J., and Hewitt, E. W. (2009). Natural killer cell cytotoxicity: how do they pull the trigger? *Immunology,* Vol. 128 (September 2009), No. 1, pp. 7-15, ISSN 0019-2805.

Torgerson, T. R. (2006). Regulatory T cells in human autoimmune diseases. *Springer Seminars in Immunopathology,* Vol. 28 (August 2006), No. 1, pp. 63-76, ISSN 0344-4325.

Van Kaer, L., Wu, M., Ichikawa, Y., Ito, K., Bonneville, M., Ostrand-Rosenberg, S., Murphy, D. B., and Tonegawa, S. (1991). Recognition of MHC TL gene products by gamma delta T cells. *Immunological Reviews,* Vol. 120 (April 1991), pp. 89-115, ISSN 0105-2896.

Van Rhijn, I., Koets, A. P., Im, J. S., Piebes, D., Reddington, F., Besra, G. S., Porcelli, S. A., van Eden, W., and Rutten, V. P. (2006). The bovine CD1 family contains group 1 CD1 proteins, but no functional CD1d. *Journal of Immunology,* Vol. 176 (April 2006), No. 8, pp. 4888-93, ISSN 0022-1767.

Van Rhijn, I., Young, D. C., De Jong, A., Vazquez, J., Cheng, T. Y., Talekar, R., Barral, D. C., Leon, L., Brenner, M. B., Katz, J. T., Riese, R., Ruprecht, R. M., O'Connor, P. B., Costello, C. E., Porcelli, S. A., Briken, V., and Moody, D. B. (2009). CD1c bypasses lysosomes to present a lipopeptide antigen with 12 amino acids. *The Journal of Experimental Medicine,* Vol. 206 (June 2009), No. 6, pp. 1409-22, ISSN 0022-1007.

Van Rhijn, I., Zajonc, D. M., Wilson, I. A., and Moody, D. B. (2005). T-cell activation by lipopeptide antigens. *Current Opinions in Immunology,* Vol. 17 (June 2005), No. 3, pp. 222-9, ISSN 0952-7915.

Vella, C., and Festenstein, H. (1992). Coxsackievirus B4 infection of the mouse pancreas: the role of natural killer cells in the control of virus replication and resistance to infection. *The Journal of General Virology,* Vol. 73 (June 1992), No. Pt 6, pp. 1379-86, ISSN 0022-1317.

Vila de Muga, M., Torre Monmany, N., Asensio Carretero, S., Traveria Casanovas, F. J., Martinez Mejias, A., Coll Sibina, M. T., and Luaces Cubells, C. (2010). [Clinical features of influenza A H1N1 2009: a multicentre study.]. *Anales de Pediatria (Barc), (March 2011), ISSN 1695-4033.*

Vincent, M. S., Xiong, X., Grant, E. P., Peng, W., and Brenner, M. B. (2005). CD1a-, b-, and c-restricted TCRs recognize both self and foreign antigens. *Journal of Immunology,* Vol. 175 (November 2005), No. 10, pp. 6344-51, ISSN 0022-1767.

Vogel, S. N., Fitzgerald, K. A., and Fenton, M. J. (2003). TLRs: differential adapter utilization by toll-like receptors mediates TLR-specific patterns of gene expression. *Molecular Interventions,* Vol. 3 (December 2003), No. 8, pp. 466-77, ISSN 1534-0384.

Vossen, M. T., Westerhout, E. M., Soderberg-Naucler, C., and Wiertz, E. J. (2002). Viral immune evasion: a masterpiece of evolution. *Immunogenetics,* Vol. 54 (November 2002), No. 8, pp. 527-42, ISSN 0093-7711.

Wang S, L. J., Wang M, Zhang J, Wang Z. (2010). Treatment and prevention of experimental autoimmune myocarditis with CD28 superagonists. *Cardiology,* Vol. 115 (January 2010), No. 2, pp. 107-113, ISSN 0008-6312.

Wiegand, J. A., Torgersen, C., Bloechlinger, S., Takala, J., and Dunser, M. W. (2010). Influenza A(H1N1) infection and severe cardiac dysfunction in adults: A case series. *Wiener Klinische Wochenschrift,* Vol. 123(February 2011), No. 3-4, pp. 120-123, ISSN 0043-5325.

Woodruff, J. (1980). Viral myocarditis. *The American Journal of Pathology,* Vol. 101 (November 1980), No 2, pp. 425-483, ISSN 0002-9440.

Wu, C. Y., Feng, Y., Qian, G. C., Wu, J. H., Luo, J., Wang, Y., Chen, G. J., Guo, X. K., and Wang, Z. J. (2010). alpha-Galactosylceramide protects mice from lethal Coxsackievirus B3 infection and subsequent myocarditis. *Clinical and Experimental Immunology,* Vol. 162 (October 2010), No. 1, pp. 178-87, ISSN 0009-9104.

Yokoyama, A. (1988). Natural killer cells in dilated cardiomyopathy. *The Tohoku Journal of Experimental Medicine.* Vol. 154 (April 1988), No. 4, pp. 335-44, ISSN 0040-8727.

Yuan, W., Dasgupta, A., and Cresswell, P. (2006). Herpes simplex virus evades natural killer T cell recognition by suppressing CD1d recycling. *Nature Immunology,* Vol. 7(August 2006), No. 8, pp. 835-42, ISSN 1529-2908.

Zajonc, D. M., Elsliger, M. A., Teyton, L., and Wilson, I. A. (2003). Crystal structure of CD1a in complex with a sulfatide self antigen at a resolution of 2.15 A. *Nature Immunology,* Vol. 4 (August 2003), No. 8, pp. 808-15, ISSN 1529-2908.

Zajonc, D. M., Savage, P. B., Bendelac, A., Wilson, I. A., and Teyton, L. (2008). Crystal structures of mouse CD1d-iGb3 complex and its cognate Valpha14 T cell receptor suggest a model for dual recognition of foreign and self glycolipids. *Journal of Molecular Biology,* Vol. 377 (April 2008), No. 4, pp. 1104-16, ISSN 0022-2836.

Zheng, Y., He, Y., Deng, J., Lu, Z., Wei, J., Yang, W., Tang, Z., Li, B., Zhang, J., Wang, L., Zhao, H., Li, X., Yu, Z., Song, P., Ma, Y., Li, Y., and Li, C. (2010). Hospitalized children with 2009 influenza a (H1N1) infection in Shenzhen, China, november-december 2009. *Pediatric Pulmonology.* Vol. 46 (March 2011), No. 3, pp. 246-252, ISSN 8755-6863.

Zingoni, A., Sornasse, T., Cocks, B. G., Tanaka, Y., Santoni, A., and Lanier, L. L. (2005). NK cell regulation of T cell-mediated responses. *Molecular Immunology,* Vol. 42 (February 2005), No. 4, pp. 451-4, ISSN 0161-5890.

Myocarditis

Edited by Dr. Daniela Cihakova

Myocarditis, the inflammation of the heart muscle, could be in some cases serious and potentially fatal disease. This book is a comprehensive compilation of studies from leading international experts on various aspects of myocarditis. The first section of the book provides a clinical perspective on the disease. It contains comprehensive reviews of the causes of myocarditis, its classification, diagnosis, and treatment. It also includes reviews of Perimyocarditis; Chagas'€™ chronic myocarditis, and myocarditis in HIV-positive patients. The second section of the book focuses on the pathogenesis of myocarditis, discussing pathways and mechanisms activated during viral infection and host immune response during myocarditis. The third, and final, section discusses new findings in the pathogenesis that may lead to new directions for clinical diagnosis, including use of new biomarkers, and new treatments of myocarditis.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

S.A. Huber (2011). Innate Lymphocyte Effectors (Natural Killer, Natural Killer T and γδ T Cells) in Infection and Myocarditis, Myocarditis, Dr. Daniela Cihakova (Ed.), ISBN: 978-953-307-289-0, InTech, Available from: http://www.intechopen.com/books/myocarditis/innate-lymphocyte-effectors-natural-killer-natural-killer-t-and-t-cells-in-infection-and-myocarditis

INTECH
open science | open minds